|Bid||0.89 x 900|
|Ask||0.95 x 900|
|Day's Range||0.9350 - 0.9790|
|52 Week Range||0.8800 - 1.9200|
|Beta (3Y Monthly)||0.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.20|
The direct benefit for Vical Incorporated (NASDAQ:VICL), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
Vical (VICL) delivered earnings and revenue surprises of 36.36% and -73.14%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 7 cents. Losses, adjusted for non-recurring gains, were 14 cents per share. The drug developer posted revenue of $47,000 in the period. ...
SAN DIEGO, Oct. 29, 2018 -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended September 30, 2018. Net loss for the third quarter of.
Vical (VICL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Vical Incorporated (NASDAQ:VICL) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...
Vical (VICL) delivered earnings and revenue surprises of 18.52% and 44.12%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 22 cents. The drug developer posted revenue of $735,000 in the period. The company's shares closed at $1.35. A year ago, they were ...
Vical Incorporated’s (NASDAQ:VICL): Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.Read More...
Understanding Vical Incorporated’s (NASDAQ:VICL) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check to gainRead More...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Vical Incorporated (NASDAQ: VICL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 12:00 PM Eastern Time. ...